menu
    • menu
    [{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Cowen"},{"orgOrder":0,"company":"F2G Limited","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ AMR Action Fund","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ AMR Action Fund"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Forbion"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Shionogi"}]

    Find Clinical Drug Pipeline Developments & Deals by F2G Limited

    Menu

    F2G Limited

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : AMR Action Fund

                            Deal Size : $100.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            F2G Raises $100M For Antifungal Drug Olorofim in U.S.

                            Details : The company will use the financing to advance its lead product candidate, F901318 (olorofim), which is in late-stage development and aimed at commercialization as a novel antifungal drug in the US.

                            Product Name : F901318

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : AMR Action Fund

                            Deal Size : $100.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            F2G Receives Complete Response Letter from FDA for New Drug Application for Olorofim for the Treatment of Inva...

                            Details : F901318 (olorofim) is F2G’s leading candidate from the orotomide class and is currently being investigated in a Phase 2b open-label study in patients who have limited treatment options for difficult-to-treat invasive, rare fungal mold infections.

                            Product Name : F901318

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 19, 2023

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal ...

                            Details : Olorofim (formerly, F901318) is F2G’s leading candidate from the orotomide class and is currently being investigated in a Phase 2b open-label study in patients who have limited treatment options for difficult-to-treat invasive, rare fungal mold infecti...

                            Product Name : F901318

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 19, 2022

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with ...

                            Details : Olorofim (formerly, F901318) is F2G’s leading candidate from the orotomide class for treatment options for difficult-to-treat invasive, rare fungal mold infections such as azole-resistant aspergillosis, scedosporiosis, lomentosporiosis, and other rare ...

                            Product Name : F901318

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 21, 2022

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Shionogi

                            Deal Size : $480.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifung...

                            Details : Under the terms of the agreement, Shionogi will conduct the clinical trials of Olorofim, a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis and other rare mold infections, and commercialization of olorofim for IA in Europe a...

                            Product Name : F901318

                            Product Type : Other Small Molecule

                            Upfront Cash : $100.0 million

                            May 16, 2022

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Shionogi

                            Deal Size : $480.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Forbion

                            Deal Size : $70.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Oloro...

                            Details : The proceeds from the financing with Shionogi & Co., Ltd., will enable F2G to advance late-stage development and commercialization in the US of F901318 (olorofim), a novel oral antifungal therapy to treat invasive aspergillosis and other rare mold infect...

                            Product Name : F901318

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 08, 2022

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Forbion

                            Deal Size : $70.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Cowen

                            Deal Size : $60.8 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            F2G Raises $61M for Late-Phase Antifungal R&D

                            Details : Proceeds from the financing will be used to fund F2G's late-stage clinical programs for their novel antifungal agent olorofim and organisational scale-up in preparation for commercialisation.

                            Product Name : F901318

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 08, 2020

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Cowen

                            Deal Size : $60.8 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            F2G Receives Second US FDA Breakthrough Therapy Designation for Olorofim

                            Details : Olorofim has been well tolerated across more than 30 years of cumulative patient dosing days with a median therapy duration of 12 weeks, in an ongoing open-label single-arm Phase 2b study in patients with proven invasive fungal disease.

                            Product Name : F901318

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 22, 2020

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            F2G Limited

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis and FDA QIDP Designation for M...

                            Details : Following the granting of Breakthrough Therapy designation in November, the U.S. FDA has also granted Qualified Infectious Disease Product (QIDP) designation to its lead first-in-class candidate, olorofim (formerly F901318).

                            Product Name : F901318

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 06, 2020

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth